ROCKVILLE, Md., Oct. 30 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. , a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders, today announced it will release results for the quarter ended September 30, 2007, on Thursday, November 8, 2007, before the market opens. A full text copy of the release will be disseminated at that time.
Mihael H. Polymeropoulos, M.D., President and Chief Executive Officer, will host a conference call to discuss the results and other corporate developments at 10:30 AM ET on Thursday, November 8, 2007. Also participating on the call will be Steven A. Shallcross, Senior Vice President and CFO. To participate in the conference call, dial the appropriate number below shortly before the 10:30 AM start time and ask for the Vanda Pharmaceuticals conference call hosted by Dr. Polymeropoulos.
The conference call will be broadcast simultaneously and archived on the Company's Web site, www.vandapharma.com. Investors should go to the Web site at least 15 minutes early to register, download, and install any necessary audio software.
A replay of the call will be available on Thursday, November 8, 2007, beginning at 12:30 PM ET and will be accessible until Thursday, November 15, 2007, at 5:00 PM ET. The replay call-in number is 1-888-286-8010 for domestic callers and 1-617-801-6888 for international callers. The access number is 60186931.
About Vanda Pharmaceuticals Inc.:
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. The company has three product candidates in clinical development. Vanda's lead product candidate, iloperidone, is a compound for the treatment of schizophrenia and bipolar disorder, and has recently submitted an NDA to the FDA for the treatment of schizophrenia. Vanda's second product candidate, VEC-162, is a compound for the treatment of sleep and mood disorders which is currently in Phase III for sleep disorders. Vanda's third product candidate, VSF-173, is a compound for the treatment of excessive sleepiness in Phase II. For more on Vanda Pharmaceuticals Inc., please visit http://www.vandapharma.com.
steven.shallcross@vandapharma.com
CONTACT: Steven A. Shallcross, Senior Vice President, Chief Financial
Officer of Vanda Pharmaceuticals Inc., +1-240-599-4500
Web site: http://www.vandapharma.com/
